Kornimate/medical-research-clean huggingface dataset:
motivational, movement and self-management training for adolescents in pain

Conditions: Chronic Pain

Summary: with this randomized controlled trial, we have three aims. first of all, to investigate underlying mechanisms that might contribute to the success of a physical activity focused self-management program in paediatric chronic pain. second of all, to determine the minimum intervention needed for improving physical activity amongst adolescents who live with chronic pain. for this we are comparing an in-person and a video-based motivational interviewing training combined with self-management techniques. third of all, to investigate the mediating effect of autonomy in adolescents with chronic pain.


Eligibility criteria:
inclusion criteria: * age between 12-18 years * experiencing pain at least 3 months * good reading, writing and listening skills in hungarian language * self-sufficient * access to internet and phone * no active cancer. exclusion criteria: * age is not between 12-18 years * experiencing pain less then 3 months * not able to read, write and listen in hungarian * not self-sufficient * no access to internet and phone * active cancer.

Keywords: chronic pain self-management adolescent motivation
instrument tissue interaction at the grasp site during membrane peeling of epiretinal membranes

Conditions: Epiretinal Membrane

Summary: epiretinal membranes are a disease of the retinal surface, that may affect visual acuity and cause metamorphopsia. using vitrectomy with membrane peeling, postoperative improvement of visual acuity and metamorphopsia may be achieved in a majority of patients. diaz et al. demonstrated that there are postoperative changes in the "nerve fiber layer" after ilm peeling, but in that study, no recording of instrument/tissue interactions was performed using ioct. the aim of this study is to examine dipping into retinal tissue with the forceps during grasping of the epiretinal membrane at the starting point of peeling with ioct.

epiretinal membranes are a disease of the retinal surface, that may affect visual acuity and cause metamorphopsia, occurring in approximately 20% of the population older than 60 years, as reported by mitchell et al.. using vitrectomy with membrane peeling, postoperative improvement of visual acuity and metamorphopsia may be achieved in a majority of patients. the surgical method has been used for some time, the first report on the surgical method of vitrectomy with membrane peeling was published by machemer and dates back to 1978. since the introduction of intraoperative optical coherence tomography (ioct), intraoperative iatrogenically induced changes in retinal tissue can be detected and correlated with postoperative changes. leisser et al. has been able to record "stretching" of the retinal tissue using this technique and has also been able to record the rarely occurring subfoveal and extrafoveal elevations of the ellipsoidal zone due to membrane peeling. these changes did not significantly affect postoperative visual acuity, according to leisser et al., but did affect the development of postoperative microscotomas. nevertheless, ioct has the potential to document instrument tissue interactions such as dipping into retinal tissue with the forceps during grasping of the erm at the starting point of membrane peeling. diaz et al. demonstrated that there are postoperative changes in the "nerve fiber layer" after ilm peeling, but in that study, no recording of instrument/tissue interactions was performed using ioct. the aim of this study is to examine dipping into retinal tissue with the forceps during grasping of the epiretinal membrane at the starting point of peeling with ioct.

Eligibility criteria:
inclusion criteria: * vitrectomy with membrane peeling with ioct assistance due to an erm in the time-period from 1.6.2014 to 31.12.2016 (early phase) or 1.11.2020 to 31.7.2022. * age 18 and older exclusion criteria: * ioct was not used during surgery * bad image quality, excluding analysis of images
the cardioprotective effects of improving potassium variability in maintenance hemodialysis patients

Conditions: Chronic Kidney Disease on Hemodialysis; Hypokalemia; Hyperkalemia; Myocardial Injury

Summary: the management of serum potassium in maintenance hemodialysis（mhd ）patients is one of the hot topics at present. in order to control hyperkalemia in dialysis patients, the use of hypokalemic dialysate is the most important measure to reduce potassium. this measure effectively reduces serum potassium, but increases the risk of hypokalemia after dialysis, which increases the risk of all-cause death in patients. hyperkalemia and hypokalemia during and at the end of dialysis are important factors for arrhythmia and death in mhd patients. due to the intermittent nature of hemodialysis treatment, mhd patients often experience frequent fluctuations in serum potassium, which is a potential risk factor for poor prognosis of mhd patients. serum potassium variability can better reflect the potassium homeostasis in mhd patients. in addition to hyperkalemia and hypokalemia, serum potassium variability is a potential risk factor affecting the prognosis of mhd patients. at present, there are few studies on the effect of improving serum potassium variability on cardiovascular complications, especially multi-center randomized controlled trials. in this study, sodium zirconium cyclosilicate was used to control hyperkalemia before dialysis and increase potassium concentration in dialysate, so as to reduce the risk of hypokalemia after dialysis, and to verify whether improving serum potassium variability can reduce myocardial injury in hemodialysis patients.


Eligibility criteria:
inclusion criteria: 1. age 18-75 years old; 2. maintenance hemodialysis ≥3 months; 3. serum potassium ≥5.0mmol/l and ≤8mmol/l before dialysis; 4. have independent ability; 5. complete clinical baseline data. exclusion criteria: 1. complicated with congenital heart disease, myocardial infarction and other heart diseases that may lead to cardiac dysfunction; 2. combined with other serious diseases, such as immune diseases, severe liver and kidney dysfunction; 3. unable to cooperate with the researcher due to mental reasons; 4. if the duration of dialysis is less than 4 hours, severe infection; 5. patients with malignant tumors or major mental disorders; 6, except primary cardiomyopathy; 7. severe constipation, intestinal obstruction, etc. 8. other investigators considered that enrollment was not recommended.

Keywords: maintenance hemodialysis potassium variability myocardial injury
the impact of ibutamoren on nonalcoholic fatty liver disease

Conditions: NAFLD; Nonalcoholic Fatty Liver; NASH - Nonalcoholic Steatohepatitis

Summary: nonalcoholic fatty liver disease (nafld), fatty infiltration of the liver in the absence of alcohol use, is an increasingly recognized complication of obesity, with prevalence estimates of about 30% of individuals in the united states. a subset of these will develop progressive disease in the form of nonalcoholic steatohepatitis (nash), which can progress to cirrhosis and liver failure. the investigators hypothesize that lum-201 (ibutamoren mesylate) will decrease intrahepatic lipid accumulation as quantified by proton magnetic resonance spectroscopy (1h-mrs).


Eligibility criteria:
inclusion criteria: 1. age 21-60yo and generally healthy 2. bmi ≥ 25 kg/m2 3. radiographic or histologic diagnosis of nafld / nash 4. insulin-like growth factor-1 (igf-1) level \<3rd quartile of normal for age exclusion criteria: 1. contraindications to mri imaging 2. diabetes mellitus or use of diabetes medications 3. history of cancer, significant renal disease, decompensated or unstable cardiovascular disease 4. cirrhosis or known liver disease other than nafld 5. pregnancy or breastfeeding 6. known pituitary or hypothalamic disease affecting the growth hormone axis 7. chronic use of drugs causing hepatic steatosis in the past 12 months (chronic oral steroids, methotrexate, tamoxifen) 8. treatment with medications that may interact with lum-201 (ibutamoren mesylate)
assessing incretin therapy for cardiovascular risk reduction and diabetes remission( itcrdr study)

Conditions: Diabetes Mellitus; Cardiovascular Diseases; Cerebrovascular Disease

Summary: this study used the diabetes prevention and follow-up research queue in daqing and the public database of ukbiobank to evaluate the risk factors of cardiovascular and cerebrovascular events in diabetes patients, and built the first risk prediction model of cardiovascular and cerebrovascular events in diabetes patients based on the chinese population follow-up queue and externally verified, so as to identify high-risk groups and guide the early prevention of cardiovascular and cerebrovascular diseases in diabetes patients. to evaluate the effect of incretin drugs on reducing the risk of cardiovascular and cerebrovascular events, and the impact on the remission rate of diabetes in people with initial diabetes, a randomized, multicenter, controlled clinical study was conducted. the long-term follow-up of 2 years was conducted to evaluate whether the cardiovascular and cerebrovascular risks of those who stopped drug treatment after remission of diabetes compared with those who continued drug treatment were reduced, as well as the long-term impact of incretin on cardiovascular and cerebrovascular risks and the role of long-term mitigation of diabetes.


Eligibility criteria:
inclusion criteria: * newly diagnosed diabetes, with no previous use of hypoglycemic medications or having discontinued such medications for more than 3 months. * blood glucose elevation detected within one year (fasting blood glucose exceeding 7 mmol/l, postprandial blood glucose or random blood glucose exceeding 11.1 mmol/l). * age between 30 and 70 years (inclusive of boundary values). * hemoglobin a1c between 7% and 10% (inclusive of boundary values). * bmi between 24 and 32.5 kg/m² (inclusive of boundary values). exclusion criteria: * history of coronary heart disease or cerebral infarction. * severe liver or kidney disease: alanine aminotransferase (alt) or aspartate aminotransferase (ast) \> 3 times the upper limit of normal (uln); glomerular filtration rate less than 30 ml/min/1.73 m². * history of malignant tumors. * use of systemic glucocorticoids (excluding local applications or inhalants) for one week or more within the three months prior to screening. * positive urine pregnancy test in women of childbearing age. * history of pancreatitis, or amylase and/or lipase \> 3 times the uln. * personal history or family history of medullary thyroid carcinoma (mtc) in first-degree relatives, or genetic predisposition to mtc (such as multiple endocrine neoplasia syndrome).
robotic locomotor experience applied to parkinson's disease

Conditions: Parkinson's Disease

Summary: gait rehabilitation with treadmill has been reported to be useful in patients with parkinson's disease. in the last years, interest in robotic devices for gait training has grew up for patients with different neurological disorders, since they minimize demands on physical therapists and may provide a more reliable and constant treatment. the aim of this study is to evaluate if robotic gait training with lokomat® can improve walking more than conventional gait training with treadmill in patients affected by parkinson's disease.


Eligibility criteria:
inclusion criteria: * patients affected by pd with a disease stage \< iii according to hoehn and yahr's classification and age \< 75 years; * absence of motor fluctuations; * able to ambulate independently; * no treadmill training for at least 6 months before the study. exclusion criteria: * current levodopa therapy started more than 6 months before enrollment; * medical or neurological pathology that contributed significantly to gait dysfunction, as musculoskeletal disease, severe osteoarthritis, peripheral neuropathy, previous lower limb joint replacement, cardiovascular disease (recent myocardial infarct, from less than 4 weeks or uncontrolled hypertension, with blood pressure \> 180/110 at rest); * hearth failure (nyha \>=3); * orthostatic hypotension; * body weight over 100 kg; * respiratory disease; * dementia; * depression; * uncorrected visual disturbances. * patients that have undergone deep brain stimulation.
atomic (active teens with multiple sclerosis) teens: a feasibility study

Conditions: Pediatric Multiple Sclerosis

Summary: taking part in recommended levels of physical activity in youth with ms may have an important and positive impact on disease symptoms, long-term disability and health outcomes. unfortunately, youth with ms are highly inactive. in order to address this issue, the investigators have developed an ms-specific mobile application for teens called active teens with multiple sclerosis (atomic). in this research the investigators will evaluate the feasibility of using the atomic program in youth with ms. the results of this pilot study will provide the data necessary to ensure the atomic program aligns with the needs of youth with ms.


Eligibility criteria:
inclusion criteria: 1. ms diagnosis following standard definitions (ipmssg); 2. edss \<4.0; 3. ability to speak english. exclusion criteria: 1. known cardiac disease, including cyanotic congenital heart disease; 2. inability to understand instructions and tolerate proposed testing or vigorous pa.
a phase iii clinical trial to assess safety and immunogenicity of a covid-19 vaccine booster dose in immunosupressed adults.

Conditions: SARS CoV 2 Infection

Summary: a phase iii, open label, single arm, multi-centre, trial to assess the immunogenicity and safety of an additional dose vaccination with a recombinant protein rbd fusion heterodimer candidate (phh-1v) against sars-cov-2, in adults with pre-existing immunosuppressive conditions vaccinated against covid-19


Eligibility criteria:
inclusion criteria: * male, female or transgender, ≥ 18 years old at day 0. * provide inform consent form * participant who has: * 3 doses of mrna vaccines * 2 doses of mrna vaccines and previous covid-19 infection * 2 doses of coronavac and 1 comirnaty, or, 1 coronavac and 2 comirnaty * participant who has: * hiv infection with cd4 tcells counts \<400 * primary antibody deficiency disorders * kidney disease on dialysis * kidney transplant at least \>1 year * auto immune disease (aid) in treatment with rituximab * for a female of childbearing potential, to have a negative pregnancy test at day 0 * use of any of these contraception: * female: hormonal contraception, intrauterine device, vasectomized partner, sexual abstinence, condom. * male: vasectomized participant, sexual abstinence, condom. exclusion criteria: * history of anaphylaxis to any prior vaccine * participants has received or plans to receive live attenuated vaccines, other not live vaccines, or vaxzevria or janssen vaccines. * pregnant or breast-feeding at day 0. * a confirmed covid-19 diagnose \<90 days prior to vaccination day 0. * a clinically significant acute illness or fever at screening or 48h before day 0. * participant had a surgery requiring hospitalisation and has not received the hospital discharge. * participant has an ongoing severe and non-stable psychiatric condition * participant has a problematic or risky use of substances including alcohol * participant has a bleeding disorder that contraindicates intramuscular injection * participant suffering from post-acute covid-19 syndrome / long covid * participant received any immunotherapy to prevent/treat covid-19 in the last 90 days * participant is already participating in another research involving drug, biologics or device * participant has donated ≥450 ml of blood products within 12 weeks before screening * participant has any medical condition and/or finding that in the investigator opinion might increase participant risk, interfere with the study or impair interpretation of study data.
magic shave powder gold's affects on the occurrence of pseudofolliculitis barbae

Conditions: Pseudofolliculitis Barbae

Summary: comparing the amount of papules, macules, pustules, and irritation caused by pseudofolluculitis barbae in subjects using depilatory cream versus traditional shaving methods.

comparing an experimental group that will remove facial hair with magic shave powder gold, and a control group that will continue using traditional shaving methods. both the subject and a physician will make observations to determine the efficacy of depilatory creams in reducing pseudofolliculits barbae.

Eligibility criteria:
inclusion criteria: * male * pfb patient exclusion criteria: * failed sensitivity testing
sustained viral response in patients achieved hbsag level≤100 iu/ml after completed interferon treatment

Conditions: Chronic Hepatitis B

Summary: chronic hepatitis b (chb) is a serious liver disease worldwide, and the leading cause of cirrhosis and hepatocellular carcinoma (hcc). hbsag loss/seroconversion is considered to be the ideal endpoint of antiviral therapy in both hbeag-positive and -negative patients, and the ultimate treatment goal in chb, however hbsag loss occurred rarely by interferon treatment. although it was reported that in nature history hbsag level≤100 iu/ml can bring good long term outcomes in patients with chronic hepatitis b. it was not clear whether patients who achieved hbsag level≤100 iu/ml by interferon treatment could maintain sustained viral response and the state of hbsag level≤100 iu/ml.

the patients with chronic hepatitis b and achieved hbsag level≤100 iu/ml after completed interferon treatment will be enrolled and observed for 96 weeks. serum hbv dna, hbsag, anti-hbs, hbeag, and anti-hbe will be measured every 3 months during the observation period, liver function tests were performed every 3 months also. the liver ultrasonic examination would be taken every 3-6 months. the primary endpoint is hbv dna reaction. the secondary endpoints is hbsag loss.

Eligibility criteria:
inclusion criteria: * patients who had chronic hepatitis b and achieved hbsag level≤100 iu/ml with undetectable hbv dna level by interferon treatment exclusion criteria: * active consumption of alcohol and/or drugs * co-infection with human immunodeficiency virus, hepatitis c virus, or hepatitis d virus * history of autoimmune hepatitis * psychiatric disease * evidence of neoplastic diseases of the liver

Keywords: hbsag loss interferon hbv reaction hepatitis b
supercharged tram evaluation in cervical esophagogastroplasty after esophagectomy

Conditions: Esophagus Cancer; Carcinoma Esophagus

Summary: esophagectomy has high rates of morbidity and mortality, in many cases due to esophagus reconstruction. anastomotic leakage and fistula are the main esophagectomy complications. many studies underwent to investigate the cause for anastomotic leakage after esophagectomy, however none of them conclude it is related to surgery or suture technique. however, it seems to be triggered by the ischemia caused after stomach mobilization to esophagus reconstruction, or even tension in the anastomosis. considering the post esophagectomy with gastroplasty high morbidity and mortality rates, strategies to create a new vascularization source and decrease anastomotic leakage rates is important. in this study researchers will evaluate whether a tram flap transfer supercharged is effective on decrease morbidity related to anastomosis ischemia in patients undergoing esophagectomy.

the transfer of muscle parts is one of the main reconstruction techniques used in plastic surgery. transverse rectus abdominis myocutaneous (tram) flap transfers are very considered due to high quality results, wide application in many cases, and small number of reviews in long term. beegle, in 1991 published a new technique of using tram supercharged in which microsurgical anastomosis are used between tram's unipedicled gastroepiploic deep artery and veins and thoracic branches and vessels, such as axillary and thoracodorsal vessels. looking for recover tissue blood perfusion and decrease morbidity rates associated with anastomosis ischemia, some studies showed large intestine or jejunum interposition plus an additional blood supply through venous and arterial anastomosis - colon or jejunum supercharged is effective. the isoperistaltic supercharged colon interposition was a good option to rebuild big esophagus parts in which stomach was not available. considering the post esophagectomy with gastroplasty high morbidity and mortality rates, strategies to create a new vascularization source and decrease anastomotic leakage rates is important. this is a single-institution, randomized clinical trial with participants recruited in the digestive system surgery clinic, at the instituto do câncer do estado de são paulo (icesp). patients will be randomized to conventional esophagectomy or tram supercharged esophagectomy, and researchers will evaluate post-operatory complications in both groups.

Eligibility criteria:
inclusion criteria: * diagnosis of esophageal malignancy cancer; * ability to understand and collaborate during treatment; exclusion criteria: * previous gastrectomy; * previous abdominal surgery with risk of altering stomach vascularization; * previous head and neck surgery with risk of alteration of cervical vessels.

Keywords: esophagectomy esophagogastroplasty supercharged
oxygenation test during general anesthesia

Conditions: Morbid Obesity

Summary: the study investigates if applying a special ventilatory strategy during anesthesia for laparoscopic gastric by pass, produces less atelectasis and better oxygenation in spite of using 100 % oxygen during pre oxygenation and induction of anesthesia. the study investigates oxygenation with blood gas samples but also with a new method that might give more information without the use of blood gas samples. primary: oxygenation in patients with morbid obesity improves if preoxygenation, induction and maintenance of anesthesia is performed with either a continuous positive airway pressure (cpap) or a positive end expiratory pressure (peep), respectively, of 10 cm h2o, in comparison to a technique without cpap but with a peep of 10 cm h2o. secondary: the improved oxygenation during anesthesia can be prolonged inte the postoperative period if emergence from anesthesia is performed without high levels of oxygen.


Eligibility criteria:
inclusion criteria: * adult patients scheduled for elective surgery of morbid obesity. * asa 1-2. (asa = american society of anesthesiologists classification). * "body mass index" (bmi) ≥ 35 but \< 50 exclusion criteria: * "asa 3" * anticipated difficult intubation. * major bleeding. * problems with ventilation necessitating protocol aberrations. * obstructive sleep apnea syndrome with cpap treatment at home. * angina pectoris
a study of prophylactic treatment for hand-foot syndrome in patients treated with oral xeloda (capecitabine).

Conditions: Breast Cancer

Summary: this 3 arm study will compare the prophylactic effect of topical corticosteroids, bepantol or placebo on hand-foot syndrome in patients receiving xeloda for treatment of metastatic breast cancer, metastatic colorectal cancer or adjuvant treatment of colorectal cancer. patients who have been receiving oral xeloda for at least 5 days will be randomized to receive prophylactic treatment with either placebo, topical corticosteroids or bepantol. the anticipated time on study treatment is until disease progression or development of hand-foot syndrome, and the target sample size is 500+ individuals.


Eligibility criteria:
inclusion criteria: * adult patients, \>=18 years of age; * breast cancer or colorectal cancer patients; * treated with oral xeloda for \<=5 days; * lack of hand-foot syndrome (palmar-plantar erythrodysesthesia). exclusion criteria: * existence of clinical symptoms suggesting hand-foot syndrome; * use of doxorubicin, 5-fu and/or cytarabine for last 3 months; * diabetes mellitus.